Rebus (RBSH) 10-Q 13 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 06, 2015
Document Information [Line Items]
Entity Registrant Name	GENSPERA INC
Entity Central Index Key	1,421,204
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	GNSZ
Entity Common Stock, Shares Outstanding		37,499,856
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,240	$ 2,316
Prepaid expenses	128	197
Total current assets	1,368	2,513
Office equipment, net of accumulated depreciation of $26 and $23	13	12
Intangible assets, net of accumulated amortization of $124 and $111	88	101
Other assets	3	3
Total assets	1,472	2,629
Current liabilities:
Accounts payable	1,004	989
Accrued expenses	2,202	1,438
Convertible notes - stockholder	105	105
Total current liabilities	3,311	2,532
Total liabilities	$ 3,311	$ 2,532
Commitments and contingencies
Stockholders’ (deficit) equity:
Preferred stock, par value $0.0001 per share; 30,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 37,237,356 and 33,181,197 shares issued and outstanding, respectively	4	3
Additional paid-in capital	42,285	39,473
Accumulated deficit	(44,128)	(39,379)
Total stockholders’ (deficit) equity	(1,839)	97
Total liabilities and stockholders’ (deficit) equity	$ 1,472	$ 2,629

CONDENSED BALANCE SHEETS _Paren

CONDENSED BALANCE SHEETS [Parenthetical] - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Office equipment, accumulated depreciation (in dollars)	$ 26	$ 23
Intangible assets, accumulated amortization (in dollars)	$ 124	$ 111
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	30,000,000	30,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	37,237,356	33,181,197
Common stock, shares outstanding	37,237,356	33,181,197

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research and development	$ 459	$ 760	$ 1,885	$ 2,788
General and administrative	915	1,035	2,864	2,553
Total operating expenses	1,374	1,795	4,749	5,341
Loss from operations	(1,374)	(1,795)	(4,749)	(5,341)
Interest income (expense), net	1	2	0	3
Loss before provision for income taxes	(1,373)	(1,793)	(4,749)	(5,338)
Provision for income taxes	0	0	0	0
Net loss	$ (1,373)	$ (1,793)	$ (4,749)	$ (5,338)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.05)	$ (0.13)	$ (0.18)
Weighted average shares outstanding (in shares)	36,856,259	32,693,788	34,569,243	29,589,182

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2014	$ 97	$ 3	$ 39,473	$ (39,379)
Balance (in shares) at Dec. 31, 2014		33,181,197
Stock-based compensation	101	$ 0	101	0
Common stock and warrants issued as payment of services and consulting fees	164	$ 0	164	0
Common stock and warrants issued as payment of services and consulting fees (in shares)		127,712
Sale of common stock and warrants at $0.70 per share	2,515	$ 1	2,514	0
Sale of common stock and warrants at $0.70 per share (in shares)		3,591,278
Issuance cost of sales of common stock and warrants	(254)	$ 0	(254)	0
Exercise of warrants	287	$ 0	287	0
Exercise of warrants (in shares)		337,169
Net loss	(4,749)	$ 0	0	(4,749)
Balance at Sep. 30, 2015	$ (1,839)	$ 4	$ 42,285	$ (44,128)
Balance (in shares) at Sep. 30, 2015		37,237,356

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) [Parenthetical]	Sep. 30, 2015$ / shares
Shares Issued, Price Per Share	$ 0.70

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (4,749)	$ (5,338)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15	18
Stock-based compensation	265	1,619
Decrease (increase) in operating assets:
Prepaid expenses	70	(13)
Increase (decrease) in operating liabilities:
Accounts payable and accrued expenses	779	(87)
Cash used in operating activities	(3,620)	(3,801)
Cash flows from investing activities:
Acquisition of office equipment	(4)	(4)
Cash used in investing activities	(4)	(4)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants sold	2,514	4,104
Cost of common stock and warrants sold	(253)	(327)
Proceeds from exercise of warrants	287	0
Cash provided by financing activities	2,548	3,777
Net decrease in cash	(1,076)	(28)
Cash and cash equivalents, beginning of period	2,316	3,587
Cash and cash equivalents, end of period	$ 1,240	$ 3,559

BACKGROUND

BACKGROUND	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	NOTE 1 – BACKGROUND GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform. Our primary focus at the present time is the clinical development of our lead compound, mipsagargin (formerly referred to as G-202), a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of mipsagargin, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We have completed a Phase II clinical trial of mipsagargin in patients with liver cancer, in which twenty-five patients were treated. In May 2015, we received a final clinical study report. We consider the study outcome achieved positive results, with 63% of treated patients having stable disease at two (2) months, and with a median time to progression of 4.5 months. These results support our plans to continue the development of mipsagargin for patients with liver cancer, as well as proceed with our clinical development strategy in other indications including glioblastoma and prostate cancer trials. Although the data from our completed trials appear promising, the outcome of our ongoing or future trials may ultimately be unsuccessful. We are currently conducting a Phase II clinical trial in glioblastoma (a type of brain cancer), in which eighteen patients have been treated as of November 6, 2015. We have elected to defer opening enrollment for our Phase II prostate clinical trial with mispsagargin until the second quarter of 2016.

MANAGEMENT'S PLANS TO CONTINUE

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	9 Months Ended
	Sep. 30, 2015
Management Plans to Continue as Going Concern [Abstract]
Management Plans to Continue as Going Concern Disclosure [Text Block]	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have an accumulated deficit of $ 44.1 To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and cash equivalents balance at September 30, 2015 was $ 1.2 84 2.2 In the event financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our auditors’ report issued in connection with our a December 31, 2014 financial statements expressed an opinion that our capital resources as of the date of their Audit Report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past December 2015. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

SUMMARY OF CRITICAL ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates. Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.5 0.8 1.9 2.8 Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140 Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of September 30, 2015, the Company has no such assets or liabilities outstanding. We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements. In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended
	Sep. 30, 2015
Supplemental Cash Flow Information [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands): Nine months ended September 30, 2015 2014 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ — $ 962 Common stock issued for consulting fees 122 — There was no cash paid for interest and income taxes for the nine months ended September 30, 2015 and 2014.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): September 30, 2015 December 31, 2014 Accrued compensation and benefits $ 1,877 $ 1,108 Accrued research and development 145 163 Accrued other 180 167 Total accrued expenses $ 2,202 $ 1,438

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2015
Notes Payable Disclosure [Abstract]
Notes Payable Disclosure [Text Block]	NOTE 6 – CONVERTIBLE NOTES PAYABLE We previously entered into convertible notes with our chief executive officer pursuant to which we borrowed an aggregate of $ 0.2 0.1 4.2 33,000 30,000 0.50

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 7 – COMMITMENTS AND CONTINGENCIES Legal Matters On July 16, 2015, the U.S. Court of Appeals for the Federal Circuit entered judgment in GenSpera, Inc. v. Annastasiah Mudiwa Mhaka in favor of GenSpera. In a per curiam order without an opinion, the Federal Circuit affirmed the decision of the U.S. District Court for the District of Maryland granting summary judgment in GenSpera's favor in two consolidated cases relating to the inventorship of two patents owned by GenSpera. The district court had issued a declaratory judgment that Dr. Annastasiah Mhaka should not be added as an inventor to the two patents at issue, and had also granted summary judgment with respect to state law tort claims brought by Dr. Mhaka against the company and two of its founders, Dr. John Isaacs and Dr. Sam Denmeade. The U.S. Court of Appeals for the Fourth Circuit previously dismissed another appeal brought by Dr. Mhaka from the same district court judgments.

CAPITAL STOCK AND STOCKHOLDER'S

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY Common Stock In September 2015, the board of directors approved amending the Company’s certificate of incorporation to effect a reverse stock split, subject to shareholder approval, of the Company’s issued and outstanding common stock at a ratio of not less than one-for-two (1 for 2), and not more than one-for thirty (1 for 30). Accordingly, the company was given the authority to take the action necessary to obtain shareholder approval at the shareholder meeting scheduled to be held on November 13, 2015. In August 2015, we cancelled and retired an aggregate of 27,288 25,000 In July 2015, we granted an aggregate of 125,000 95 30,000 27 In July 2015, we also offered and sold 3,591,278 0.70 0.80 0.70 During the nine months ended September 30, 2015, 337,169 287,000

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 9 – STOCK OPTIONS Our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) allow for the issuance of up to 6,000,000 12,000,000 Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the nine months ended September 30, 2015 and 2014 was as follows: Nine months ended September 30, 2015 2014 Research and development $ 28 $ 25 General and administrative 73 249 $ 101 $ 274 The following table summarizes stock option activity under the Plans: Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 8,685,095 $ 1.65 Granted 376,600 $ 0.79 Exercised — — Forfeited (140,000) $ 2.17 Outstanding at September 30, 2015 8,921,695 $ 1.60 3.3 $ — Exercisable at September 30, 2015 8,712,445 $ 1.62 3.3 $ — As of September 30, 2015, there was approximately $ 72,000 During the nine months ended September 30, 2015, we issued options to purchase 159,000 217,600 1,948,902 159,000 391,570 The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2015 and 2014: Nine months ended September 30, 2015 2014 Volatility 58.4 % 55.6 % Expected term (years) 3.4 3.3 Risk-free interest rate 1.0 % 0.6 % Dividend yield 0 % 0 %

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 10 – WARRANTS We account for common stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price. As of September 30, 2015, there were no outstanding liability-classified warrants. Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 19,897,928 $ 1.54 Granted 7,694,859 $ 0.75 Exercised (337,169) $ 0.70 Forfeited (1,236,035) $ 3.16 Outstanding at September 30, 2015 26,019,583 $ 1.24 2.3 $ — Exercisable at September 30, 2015 26,019,583 $ 1.24 2.3 $ — During the nine 337,169 287,000 Weighted- average Number of exercise shares price Expiration Issued to consultants 1,057,667 $ 1.91 December 2015 through May 2020 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2015 through June 2019 Issued pursuant to 2014 financings 7,469,859 $ 0.75 January 2017 through July 2020 26,019,583 During the nine months ended September 30, 2015, in connection with a private placement, we issued an aggregate of 7,469,859 7,182,556 287,303 0.70 0.80 225,000 0.65 0.30 During the nine months ended September 30, 2014, in connection with a registered offering, we issued an aggregate of 10,736,722 10,409,905 326,817 0.85 1.15 483,125 1.15 3,826,792 4,163,961 0.70 December 31, 2016 During the nine months ended September 30, 2014, we issued warrants to consultants to purchase 248,000 1.15 3.00 0.36 Total stock-based compensation expense of approximately $ 67,000 90,000 Nine months ended September 30, 2015 2014 Volatility 72.7 % 52.0 % Expected term (years) 1.7 2.0 Risk-free interest rate 0.6 % 0.5 % Dividend yield 0 % 0 %

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11 – SUBSEQUENT EVENTS In October 2015, the board of directors approved amending the conversion price of the convertible notes entered into with our chief executive officer from a price of $ 0.50 0.40 262,500 In November 2015, we issued a warrant to a consultant to purchase 75,000 0.35 0.15

SUMMARY OF CRITICAL ACCOUNTIN19

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses. We incurred research and development expenses of approximately $ 0.5 0.8 1.9 2.8
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3: Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. As of September 30, 2015, the Company has no such assets or liabilities outstanding.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2014, the FASB issued Accounting Standards Update “ASU” 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update provides guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments contained in this update are effective for public and nonpublic entities for annual periods ending after December 15, 2016. We are currently assessing the impact of the adoption of ASU 2014-15, and we have not yet determined the effect of the standard on our ongoing financial reporting. In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, simplifying the income statement presentation. The guidance does not change the requirement to disclose items that are unusual in nature and occur infrequently. ASU No. 2015-01 is effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, although early adoption is permitted. Exclusive of a material transaction that would qualify for extraordinary item presentation in future periods, we do not expect the adoption of this standard to materially impact our financial statements. In April 2015, the Financial Accounting Standard Board issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2015, and early adoption is permitted. We do not expect the adoption of this standard to materially impact our consolidated financial statements. There are various other recently issued updates, most of which represented technical corrections to the accounting literature or application to specific industries, and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY OF CRITICAL ACCOUNTIN20

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2015 and 2014, as they would be anti-dilutive: Nine months ended September 30, 2015 2014 Shares underlying options outstanding 8,921,695 8,425,095 Shares underlying warrants outstanding 26,019,583 19,897,928 Shares underlying convertible notes outstanding 276,936 268,117 35,218,214 28,591,140

SUPPLEMENTAL CASH FLOW INFORM21

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2015
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The following table contains additional information for the periods reported (in thousands): Nine months ended September 30, 2015 2014 Non-cash financial activities: Common stock options issued as payment of accrued compensation $ — $ 962 Common stock issued for consulting fees 122 —

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following (in thousands): September 30, 2015 December 31, 2014 Accrued compensation and benefits $ 1,877 $ 1,108 Accrued research and development 145 163 Accrued other 180 167 Total accrued expenses $ 2,202 $ 1,438

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of operations for the nine months ended September 30, 2015 and 2014 was as follows: Nine months ended September 30, 2015 2014 Research and development $ 28 $ 25 General and administrative 73 249 $ 101 $ 274
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity under the Plans: Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 8,685,095 $ 1.65 Granted 376,600 $ 0.79 Exercised — — Forfeited (140,000) $ 2.17 Outstanding at September 30, 2015 8,921,695 $ 1.60 3.3 $ — Exercisable at September 30, 2015 8,712,445 $ 1.62 3.3 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2015 and 2014: Nine months ended September 30, 2015 2014 Volatility 58.4 % 55.6 % Expected term (years) 3.4 3.3 Risk-free interest rate 1.0 % 0.6 % Dividend yield 0 % 0 %

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Share-based Compensation, Activity [Table Text Block]	Transactions involving our equity-classified warrants are summarized as follows: Weighted- Weighted-average Aggregate average remaining intrinsic Number of exercise contractual term value (in shares price (in years) thousands) Outstanding at December 31, 2014 19,897,928 $ 1.54 Granted 7,694,859 $ 0.75 Exercised (337,169) $ 0.70 Forfeited (1,236,035) $ 3.16 Outstanding at September 30, 2015 26,019,583 $ 1.24 2.3 $ — Exercisable at September 30, 2015 26,019,583 $ 1.24 2.3 $ —
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	The following table summarizes outstanding common stock purchase warrants as of September 30, 2015: Weighted- average Number of exercise shares price Expiration Issued to consultants 1,057,667 $ 1.91 December 2015 through May 2020 Issued pursuant to 2011 financings 1,936,785 $ 3.24 January 2016 through April 2016 Issued pursuant to 2012 financings 296,366 $ 3.00 December 2017 Issued pursuant to 2013 financings 4,376,228 $ 1.97 December 2017 through August 2018 Issued pursuant to 2014 financings 10,882,678 $ 0.82 December 2015 through June 2019 Issued pursuant to 2014 financings 7,469,859 $ 0.75 January 2017 through July 2020 26,019,583
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2015 and 2014: Nine months ended September 30, 2015 2014 Volatility 72.7 % 52.0 % Expected term (years) 1.7 2.0 Risk-free interest rate 0.6 % 0.5 % Dividend yield 0 % 0 %

MANAGEMENT'S PLANS TO CONTINU25

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Management Plan [Line Items]
Deficit accumulated during the development stage		$ (44,128)	$ (39,379)
Cash and Cash Equivalents, at Carrying Value		$ 1,240	$ 2,316	$ 3,559	$ 3,587
Percentage of Cash and Cash Equivalents in Total Assets		84.00%
Proceeds from Issuance of Common Stock and Warrants	$ 2,200

SUMMARY OF CRITICAL ACCOUNTIN26

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	35,218,214	28,591,140
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	276,936	268,117
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	26,019,583	19,897,928
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares underlying, outstanding	8,921,695	8,425,095

SUMMARY OF CRITICAL ACCOUNTIN27

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Summary Of Critical Accounting Policies [Line Items]
Research and Development Expense, Total	$ 459	$ 760	$ 1,885	$ 2,788

SUPPLEMENTAL CASH FLOW INFORM28

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Non-cash financial activities:
Common stock options issued as payment of accrued compensation	$ 0	$ 962
Common stock issued for consulting fees	$ 122	$ 0

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Accrued compensation and benefits	$ 1,877	$ 1,108
Accrued research and development	145	163
Accrued other	180	167
Total accrued expenses	$ 2,202	$ 1,438

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 100,000
Debt Instrument, Interest Rate, Effective Percentage	4.20%
Debt Instrument, Maturity Date	Dec. 6, 2011
Debt Instrument, Increase, Accrued Interest	$ 33,000	$ 30,000
Debt Instrument, Convertible, Conversion Price	$ 0.50
Chief Executive Officer [Member]
Debt Instrument [Line Items]
Convertible Notes Payable, Total	$ 200,000

CAPITAL STOCK AND STOCKHOLDER31

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) - USD ($)	1 Months Ended			9 Months Ended
	Aug. 31, 2015	Jul. 31, 2015	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services		125,000
Stock Issued During Period, Value, Issued for Services		$ 95,000		$ 164,000
Number of Warrants Exercised				337,169
Proceeds from Warrant Exercises				$ 287,000	$ 0
Shares Issued, Price Per Share				$ 0.70
Business Advisory Services [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Forfeited	$ 25,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited	27,288
Consultant [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services			30,000
Stock Issued During Period, Value, Issued for Services			$ 27,000
Consultant [Member] | Business And Advisory Services [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				3,591,278
Stock Issued During Period, Shares, Issued for Services				127,712
Stock Issued During Period, Value, Issued for Services				$ 0
Number of Warrants Exercised				337,169
Proceeds from Warrant Exercises				$ 287,000
Series E Warrant [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share		$ 0.70
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		3,591,278
Shares Issued, Price Per Share		$ 0.70

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 101	$ 274
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	28	25
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 73	$ 249

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	8,685,095
Number of shares, Granted (in shares)	376,600
Number of shares, Exercised (in shares)	0
Number of shares, Forfeited (in shares)	(140,000)
Number of shares, Outstanding at end of period (in shares)	8,921,695
Number of shares, Exercisable at September 30, 2015 (in shares)	8,712,445
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 1.65
Weighted-average exercise price, Granted (in dollars per share) | $ / shares	0.79
Weighted-average exercise price, Exercised (in dollars per share) | $ / shares	0
Weighted-average exercise price, Forfeited (in dollars per share) | $ / shares	2.17
Weighted-average exercise price, Outstanding at end of period (in dollars per share) | $ / shares	1.60
Weighted-average exercise price, Exercisable at September 30, 2015 (in dollars per share) | $ / shares	$ 1.62
Weighted-average remaining contractual term, Outstanding at September 30, 2015	3 years 3 months 18 days
Weighted-average remaining contractual term, Exercisable at September 30, 2015	3 years 3 months 18 days
Aggregate intrinsic value, Outstanding at September 30, 2015 (in dollars) | $	$ 0
Aggregate intrinsic value, Exercisable at September 30, 2015 (in dollars) | $	$ 0

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	58.40%	55.60%
Expected term (years)	3 years 4 months 24 days	3 years 3 months 18 days
Risk-free interest rate	1.00%	0.60%
Dividend yield	0.00%	0.00%

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 72,000
Share Based Compensation Arrangement Options Issued To Non Employee Directors	159,000	159,000
Share Based Compensation Arrangement Options Issued To Consultants	217,600	391,570
Share Based Compensation Arrangement Options Issued To Employee Directors		1,948,902
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000
Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	12,000,000

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding at beginning of period (in shares)	19,897,928
Number of shares, Granted (in shares)	7,694,859
Number of shares, Exercised (in shares)	(337,169)
Number of shares, Forfeited (in shares)	(1,236,035)
Number of shares, Outstanding at ending of period (in shares)	26,019,583
Number of shares, Exercisable at September 30, 2015 (in shares)	26,019,583
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 1.54
Weighted-average exercise price, Granted (in dollars per share) | $ / shares	0.75
Weighted-average exercise price, Exercised (in dollars per share) | $ / shares	0.70
Weighted-average exercise price, Forfeited (in dollars per share) | $ / shares	3.16
Weighted-average exercise price, Outstanding at end of period (in dollars per share) | $ / shares	1.24
Weighted-average exercise price, Exercisable at September 30, 2015 (in dollars per share) | $ / shares	$ 1.24
Weighted-average remaining contractual term, Outstanding	2 years 3 months 18 days
Weighted-average remaining contractual term, Exercisable at September 30, 2015	2 years 3 months 18 days
Aggregate intrinsic value, Outstanding (in dollars) | $	$ 0
Aggregate intrinsic value, Exercisable at September 30, 2015 (in dollars) | $	$ 0

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity-classified warrants [Abstract]
Number of shares (in shares)	26,019,583
Equity Classified Warrants [Member]
Equity-classified warrants [Abstract]
Weighted Average Exercise price (in dollars per share)		$ 1.15
Equity Classified Warrants [Member] | Consultant [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,057,667
Weighted Average Exercise price (in dollars per share)	$ 1.91
Investment Warrants Expiration Date Range Start	Dec. 31, 2015
Investment Warrants Expiration Date Range End	May 31, 2020
Equity Classified Warrants [Member] | Financing 2011 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	1,936,785
Weighted Average Exercise price (in dollars per share)	$ 3.24
Investment Warrants Expiration Date Range Start	Jan. 1, 2016
Investment Warrants Expiration Date Range End	Apr. 30, 2016
Equity Classified Warrants [Member] | Financing 2012 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	296,366
Weighted Average Exercise price (in dollars per share)	$ 3
Investment Warrants Expiration Date Range Start	Dec. 31, 2017
Investment Warrants Expiration Date	Dec. 31, 2017
Equity Classified Warrants [Member] | Financing 2013 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	4,376,228
Weighted Average Exercise price (in dollars per share)	$ 1.97
Investment Warrants Expiration Date Range End	Aug. 31, 2018
Equity Classified Warrants [Member] | Financing 2014 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	10,882,678
Weighted Average Exercise price (in dollars per share)	$ 0.82
Investment Warrants Expiration Date Range Start	Dec. 31, 2015
Investment Warrants Expiration Date Range End	Jun. 30, 2019
Equity Classified Warrants [Member] | Financing 2015 [Member]
Equity-classified warrants [Abstract]
Number of shares (in shares)	7,469,859
Weighted Average Exercise price (in dollars per share)	$ 0.75
Investment Warrants Expiration Date Range Start	Jan. 31, 2017
Investment Warrants Expiration Date Range End	Jul. 31, 2020

WARRANTS (Details 2)

WARRANTS (Details 2) - Warrant [Member]	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Volatility	72.70%	52.00%
Expected term (years)	1 year 8 months 12 days	2 years
Risk-free interest rate	0.60%	0.50%
Dividend yield	0.00%	0.00%

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Warrants And Derivative Warrant Liability [Line Items]
Warrants Exercised		337,169
Proceeds from Warrant Exercises		$ 287,000	$ 0
Share Based Compensation Expense Recognized For Warrants Issued To Consultants		$ 67,000	$ 90,000
Series B and C Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
WarrantsExpirationDate		Dec. 31, 2016
Private Offering [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues	483,125
Consultants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues		7,469,859
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		225,000	248,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.65
Warrants Weighted Average Fair Value		0.30	0.36
Placement Agent [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues		287,303	326,817
Investor [Member]
Warrants And Derivative Warrant Liability [Line Items]
Stock Issued During Period, Shares, New Issues		7,182,556	10,409,905
Maximum [Member] | Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3
Minimum [Member] | Business And Advisory Services [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.15
Equity Classified Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Shares Issued During Period Upon Exercise of Warrants			10,736,722
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.15
Equity Classified Warrants [Member] | Maximum [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.80	1.15
Equity Classified Warrants [Member] | Minimum [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.70	0.85
Series B Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.70
Warrants Amended During The Period			3,826,792
Series C Warrants [Member]
Warrants And Derivative Warrant Liability [Line Items]
Warrants Amended During The Period			4,163,961

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - Subsequent Event [Member] - $ / shares	1 Months Ended
	Nov. 30, 2015	Oct. 31, 2015
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.35
Stock Issued During Period, Shares, New Issues	75,000
Common Stock, Conversion Basis		262,500
Fair Value Assumptions, Weighted Average Expected Dividend	$ 0.15
Chief Executive Officer [Member] | Maximum [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.50
Chief Executive Officer [Member] | Minimum [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.40